Skip to main content
SpringerLink
Log in

What’s New in Diagnostic Testing and Treatment Approaches for Mycoplasma pneumoniae Infections in Children?

  • Chapter
  • First Online:
Hot Topics in Infection and Immunity in Children VIII

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 719))

Abstract

M. pneumoniae is a common cause of upper and lower respiratory tract infections in persons of all ages, including the very young and the very old. Extrapulmonary complications involving any organ system may accompany respiratory tract manifestations, or they may occur in persons without an obvious respiratory component to their illness. Clinical presentation is similar enough to other causes of respiratory infection that presentation alone cannot be used reliably to identify children in whom a mycoplasmal etiology is likely and coinfection with other bacterial or viral pathogens is common. Due to the many limitations of culture and serology, PCR is the preferred method for laboratory diagnosis, although it is not yet widely available in many countries. Macrolides have historically been the antibiotics of choice for children with mycoplasmal infections, but the emergence of clinically significant high-level resistance worldwide has necessitated a reevaluation of their use, particularly in locations where resistance is common. Consideration of alternatives such as tetracyclines and fluoroquinolones, even though these agents are not normally considered in younger children due to potential toxicities.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Atkinson TP, Boppana S, Theos A, CLements LS, Xiao L, Waites K. Stevens-Johnson Syndrome in a patient with macrolide-resistant Mycoplasma pneumoniae. Pediatrics 2011;127:e1605–1609.

    Google Scholar 

  2. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004;17(4):697–728.

    Article  PubMed  CAS  Google Scholar 

  3. Foy HM. Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin Infect Dis 1993;17 Suppl 1:S37–46.

    Article  PubMed  Google Scholar 

  4. Block S, Hedrick J, Hammerschlag MR, Cassell GH, Craft JC. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J 1995;14(6):471–7.

    Article  PubMed  CAS  Google Scholar 

  5. Korppi M, Heiskanen-Kosma T, Kleemola M. Incidence of community-acquired pneumonia in children caused by Mycoplasma pneumoniae: serological results of a prospective, population-based study in primary health care. Respirology 2004;9(1):109–14.

    Article  PubMed  Google Scholar 

  6. Layani-Milon MP, Gras I, Valette M, Luciani J, Stagnara J, Aymard M, et al. Incidence of upper respiratory tract Mycoplasma pneumoniae infections among outpatients in Rhone-Alpes, France, during five successive winter periods. J Clin Microbiol 1999;37(6):1721–6.

    PubMed  CAS  Google Scholar 

  7. Esposito S, Blasi F, Bosis S, Droghetti R, Faelli N, Lastrico A, et al. Aetiology of acute pharyngitis: the role of atypical bacteria. J Med Microbiol 2004;53(Pt 7):645–51.

    Article  PubMed  Google Scholar 

  8. Esposito S, Bosis S, Begliatti E, Droghetti R, Tremolati E, Tagliabue C, et al. Acute tonsillopharyngitis associated with atypical bacterial infection in children: natural history and impact of macrolide therapy. Clin Infect Dis 2006;43(2):206–9.

    Article  PubMed  Google Scholar 

  9. Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev 2008;32(6):956–73.

    Article  PubMed  CAS  Google Scholar 

  10. Waites KB, Balish MF, Atkinson TP. New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiol 2008;3(6):635–48.

    Article  PubMed  Google Scholar 

  11. Kannan TR, Baseman JB. ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens. Proc Natl Acad Sci U S A 2006;103(17):6724–9.

    Article  PubMed  CAS  Google Scholar 

  12. Dallo SF, Baseman JB. Intracellular DNA replication and long-term survival of pathogenic mycoplasmas. Microb Pathog 2000;29(5):301–9.

    Article  PubMed  CAS  Google Scholar 

  13. Roifman CM, Rao CP, Lederman HM, Lavi S, Quinn P, Gelfand EW. Increased susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia. Am J Med 1986;80(4):590–4.

    Article  PubMed  CAS  Google Scholar 

  14. Waites KB, Simecka JW, Talkington DF, Atkinson TP. Pathogensis of Mycoplasma pneumoniae infections: adaptive immunity, innate immuinity, cell biology and virulence factors. In: Suttorp N, Welte T, Marre R, editors. Community-acquired pneumonia. Basel, Switzerland: Burkhauser Verlag; 2007. p. 183–99.

    Chapter  Google Scholar 

  15. Narita M. Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia. J Infect Chemother 2010;16(3):162–9.

    Article  PubMed  Google Scholar 

  16. Loens K, Goossens H, Ieven M. Acute respiratory infection due to Mycoplasma pneumoniae: current satus of diagnostic methods. Eur J Clin Microbiol Infect Dis 2010;29:1055–69.

    Article  PubMed  CAS  Google Scholar 

  17. Beersma MF, Dirven K, van Dam AP, Templeton KE, Claas EC, Goossens H. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the “gold standard”. J Clin Microbiol 2005;43(5):2277–85.

    Article  PubMed  CAS  Google Scholar 

  18. Talkington DF, Shott S, Fallon MT, Schwartz SB, Thacker WL. Analysis of eight commercial enzyme immunoassay tests for detection of antibodies to Mycoplasma pneumoniae in human serum. Clin Diagn Lab Immunol 2004;11(5):862–7.

    PubMed  CAS  Google Scholar 

  19. Ozaki T, Nishimura N, Ahn J, Watanabe N, Muto T, Saito A, et al. Utility of a rapid diagnosis kit for Mycoplasma pneumoniae pneumonia in children, and the antimicrobial susceptibility of the isolates. J Infect Chemother 2007;13(4):204–7.

    Article  PubMed  CAS  Google Scholar 

  20. Daxboeck F, Khanakah G, Bauer C, Stadler M, Hofmann H, Stanek G. Detection of Mycoplasma pneumoniae in serum specimens from patients with mycoplasma pneumonia by PCR. Int J Med Microbiol 2005;295(4):279–85.

    Article  PubMed  CAS  Google Scholar 

  21. Dumke R, Jacobs E. Comparison of commercial and in-house real-time PCR assays used for detection of Mycoplasma pneumoniae. J Clin Microbiol 2009;47(2):441–4.

    Article  PubMed  CAS  Google Scholar 

  22. Loens K, Mackay WG, Scott C, Goossens H, Wallace P, Ieven M. A multicenter pilot external quality assessment programme to assess the quality of molecular detection of Chlamydophila pneumoniae and Mycoplasma ­pneumoniae. J Microbiol Methods 2010;82(2):131–5.

    Article  PubMed  CAS  Google Scholar 

  23. McCracken GH, Jr. Current status of antibiotic treatment for Mycoplasma pneumoniae infections. Pediatr Infect Dis 1986;5(1):167–71.

    Article  PubMed  Google Scholar 

  24. Harris JA, Kolokathis A, Campbell M, Cassell GH, Hammerschlag MR. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J 1998;17(10):865–71.

    Article  PubMed  CAS  Google Scholar 

  25. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, et al. Increased Macrolide Resistance of Mycoplasma pneumoniae in Pediatric Patients with Community-Acquired Pneumonia. Antimicrob Agents Chemother 2008;52(1):348–50.

    Article  PubMed  CAS  Google Scholar 

  26. Suzuki S, Yamazaki T, Narita M, Okazaki N, Suzuki I, Andoh T, et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother 2006;50(2):709–12.

    Article  PubMed  CAS  Google Scholar 

  27. Matsuoka M, Narita M, Okazaki N, Ohya H, Yamazaki T, Ouchi K, et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother 2004;48(12):4624–30.

    Article  PubMed  CAS  Google Scholar 

  28. Morozumi M, Hasegawa K, Kobayashi R, Inoue N, Iwata S, Kuroki H, et al. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23 S rRNA gene mutation. Antimicrob Agents Chemother 2005;49(6):2302–6.

    Article  PubMed  CAS  Google Scholar 

  29. Xin D, Mi Z, Han X, Qin L, Li J, Wei T, et al. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agents Chemother 2009;53(5):2158–9.

    Article  PubMed  CAS  Google Scholar 

  30. Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae ­isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother 2009;53(5):2160–2.

    Article  PubMed  CAS  Google Scholar 

  31. Peuchant O, Menard A, Renaudin H, Morozumi M, Ubukata K, Bebear CM, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother 2009;64(1):52–8.

    Article  PubMed  CAS  Google Scholar 

  32. Wolff BJ, Thacker WL, Schwartz SB, Winchell JM. Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob Agents Chemother 2008;52(10):3542–9.

    Article  PubMed  CAS  Google Scholar 

  33. Miyashita N, Maruyama T, Kobayashi T, Kobayashi H, Taguchi O, Kawai Y, et al. Community-acquired macrolide-resistant Mycoplasma pneumoniae pneumonia in patients more than 18 years of age. J Infect Chemother.

    Google Scholar 

  34. Li X, Atkinson TP, Hagood J, Makris C, Duffy LB, Waites KB. Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr Infect Dis J 2009;28(8):693–6.

    Article  PubMed  Google Scholar 

  35. Dumke R, Schurwanz N, Lenz M, Schuppler M, Luck C, Jacobs E. Sensitive detection of Mycoplasma pneumoniae in human respiratory tract samples by optimized real-time PCR approach. J Clin Microbiol 2007;45(8):2726–30.

    Article  PubMed  CAS  Google Scholar 

  36. Lopez-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol 2008;8(3):286–91.

    Article  PubMed  CAS  Google Scholar 

  37. Duffy LB, Crabb DM, Bing X, Waites KB. Bactericidal activity of levofloxacin against Mycoplasma pneumoniae. J Antimicrob Chemother 2003;52(3):527–8.

    Article  PubMed  CAS  Google Scholar 

  38. Chien S, Wells TG, Blumer JL, Kearns GL, Bradley JS, Bocchini JA, Jr., et al. Levofloxacin Pharmacokinetics in Children. J Clin Pharmacol 2005;45(2):153–60.

    Article  PubMed  CAS  Google Scholar 

  39. Smilack JD, Burgin WW, Jr., Moore WL, Jr., Sanford JP. Mycoplasma pneumoniae pneumonia and clindamycin therapy. Failure to demonstrate efficacy. Jama 1974;228(6):729–31.

    Article  PubMed  CAS  Google Scholar 

  40. Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob Agents Chemother 2009;53(5):2139–41.

    Article  PubMed  CAS  Google Scholar 

  41. Talkington DF, Waites KB, Schwartz SB, Besser RE. Emerging from obscurity: understanding pulmonary and exrrapulmonary syndromes, pathogenesis, and epidemiology of human Mycoplasma pneumoniae infections. In: Scheld WM, Craig WA, Hughes JM, editors. Emerging Infections 5. Washington, D.C.: American Society for Microbiology; 2001. p. 57–84.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Alabama at Birmingham, Alabama, USA

    Ken B. Waites

Authors
  1. Ken B. Waites
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ken B. Waites .

Editor information

Editors and Affiliations

  1. Royal Children's Hosp., Dept. Paediatrics, University of Melbourne, Parkville, 3052, Victoria, Australia

    Nigel Curtis

  2. Institute of Child Life and Health, UBHT Education Centre, University of Bristol, Upper Maudlin Street, Bristol, BS2 8AE, United Kingdom

    Adam Finn

  3. University of Oxford, Level 4,John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom

    Andrew J. Pollard

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Waites, K.B. (2012). What’s New in Diagnostic Testing and Treatment Approaches for Mycoplasma pneumoniae Infections in Children?. In: Curtis, N., Finn, A., Pollard, A. (eds) Hot Topics in Infection and Immunity in Children VIII. Advances in Experimental Medicine and Biology, vol 719. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-0204-6_5

Download citation

Publish with us

Policies and ethics

Search

Navigation